Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A fluorogenic probe for predicting treatment response in non-small cell lung cancer with EGFR-activating mutations.

Nature communications - 14 Nov 2022

Deng Hui, Lei Qian, Wang Chengdi, Wang Zhoufeng, Chen Hai, Wang Gang, Yang Na, Huang Dan, Yu Quanwei, Yao Mengling, Xiao Xue, Zhu Guonian, Cheng Cheng, Li Yangqian, Li Feng, Tian Panwen, Li Weimin

Abstract excerpt

Therapeutic responses of non-small cell lung cancer (NSCLC) to epidermal growth factor receptor (EGFR) - tyrosine kinase inhibitors (TKIs) are known to be associated with EGFR mutations. However, a proportion of NSCLCs carrying EGFR mutations still progress on EGFR-TKI underlining the imperfect correlation. Structure-function-based approaches have recently been reported to perform better in retrospectively...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Lung Cancer Research Studies

Share to Lung Cancer Treatments and Mutations

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 36376325
DOI: 10.1038/s41467-022-34627-5
PMCID: PMC9663578

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A fluorogenic probe for predicting treatment response in non-small cell lung cancer with EGFR-activating mutations.PMID 36376325Read ↗

Image-Based Phenotypic Profiling Enables Rapid and Accurate Assessment of EGFR-Activating Mutations in Tissues from Lung Cancer Patients.Semantic proximity Read ↗

Structure-based classification predicts drug response in EGFR-mutant NSCLC.Semantic proximity Read ↗

Predictive radiogenomics modeling of EGFR mutation status in lung cancer.Semantic proximity Read ↗

A PET imaging approach for determining EGFR mutation status for improved lung cancer patient management.Semantic proximity Read ↗

Current progress and quality of radiomic studies for predicting EGFR mutation in patients with non-small cell lung cancer using PET/CT images: a systematic review.Semantic proximity Read ↗

Machine Learning-Based Radiomics for Prediction of Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma.Semantic proximity Read ↗

Quantum Cascade Laser-Based Infrared Imaging as a Label-Free and Automated Approach to Determine Mutations in Lung Adenocarcinoma.Semantic proximity Read ↗

Structure-based classification of EGFR mutations informs inhibitor selection for lung cancer therapy.Semantic proximity Read ↗

Expanded Application of a Photoaffinity Probe to Study Epidermal Growth Factor Receptor Tyrosine Kinase with Functional Activity.Semantic proximity Read ↗

EGFR protein expression in non-small cell lung cancer predicts response to an EGFR tyrosine kinase inhibitor--a novel antibody for immunohistochemistry or AQUA technology.Semantic proximity Read ↗

First-generation epidermal growth factor receptor inhibitors in non-small cell lung cancer: clinical impact of the epidermal growth factor receptor fluorescence in situ hybridization assay.Semantic proximity Read ↗

Impact of experimental design on PET radiomics in predicting somatic mutation status.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.